Optimization of Atopic Dermatitis Treatment That Requires Second-line Systemic Therapy Through Predictive Models - Trial NCT06366932
Access comprehensive clinical trial information for NCT06366932 through Pure Global AI's free database. This Phase 4 trial is sponsored by Instituto de Investigación Hospital Universitario La Paz and is currently Recruiting. The study focuses on Atopic Dermatitis. Target enrollment is 150 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Instituto de Investigación Hospital Universitario La Paz
Timeline & Enrollment
Phase 4
Sep 25, 2023
Sep 01, 2025
Primary Outcome
Percentage of patients with primary non-response to second-line treatment.
Summary
This is a low-intervention phase IV trial. The main objective is to optimize the treatment of
 patients with moderate-severe atopic dermatitis that require systemic treatment after
 failure, intolerance or contraindication to cyclosporine.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06366932
Non-Device Trial